Standard BioTools And 2 Other Promising Penny Stocks For Your Watchlist

The market remained flat over the last week but is up 17% over the past year, with earnings forecast to grow by 17% annually. Investing in penny stocks—once a buzzword but now more of a niche—can still open doors to growth opportunities, typically in smaller or newer companies. We'll spotlight several penny stocks that stand out for their financial strength, making them promising candidates for investors seeking under-the-radar companies poised for long-term success.

Underneath we present a selection of stocks filtered out by our screen.

Standard BioTools (LAB)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Standard BioTools Inc. develops, manufactures, and sells instrumentation, consumables, and services for scientists and biomedical researchers worldwide, with a market cap of $255.37 million.

Operations: The company generates revenue from its Medical Products segment, which totaled $84.60 million.

Market Cap: $255.37M

Standard BioTools Inc. is navigating a challenging landscape, marked by its unprofitability and recent volatility in share price. Despite having more cash than debt and a substantial cash runway exceeding three years, the company faces delisting risks from Nasdaq due to its stock trading below US$1 for an extended period. Recent earnings showed a slight decline in revenue to US$20.1 million for Q2 2026, with net losses narrowing compared to the previous year. The pending merger with Treeline Biosciences could reshape its future, though it has withdrawn full-year guidance amidst this transition.

• Dive into the specifics of Standard BioTools here with our thorough balance sheet health report.
• Review our growth performance report to gain insights into Standard BioTools' future.

Resources Connection (RGP)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Resources Connection, Inc., operating under the Resources Global Professionals name, offers professional services to business customers across North America, the Asia Pacific, and Europe with a market cap of approximately $154 million.

Operations: The company's revenue is primarily generated through three segments: Consulting ($159.80 million), On-demand Talent ($168.80 million), and Outsourced Services ($39.21 million), with additional contributions from operations in Europe & Asia Pacific totaling $75.14 million.

Market Cap: $153.96M

Resources Connection, Inc. faces challenges as a penny stock with recent declines in sales and ongoing unprofitability, reporting a net loss of US$40.6 million for the fiscal year ending May 2026. Despite these hurdles, the company maintains financial stability with no debt and sufficient short-term assets to cover liabilities. Recent strategic moves include securing a US$30 million credit facility to support working capital needs and potential growth opportunities. The firm has also restructured its board for better governance and appointed key leadership in AI practice to enhance service offerings, indicating efforts toward operational improvement amidst market volatility.

• Navigate through the intricacies of Resources Connection with our comprehensive balance sheet health report here.
• Evaluate Resources Connection's prospects by accessing our earnings growth report.

CI&T (CINT)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: CI&T Inc. is a global provider of strategy, design, and software engineering services with a market cap of $433.88 million.

Operations: The company's revenue is primarily generated from its Computer Services segment, which accounted for $541.02 million.

Market Cap: $433.88M

CI&T Inc. demonstrates a stable financial foundation with short-term assets exceeding both its long-term and short-term liabilities, reflecting prudent financial management. The company's recent strategic initiatives, such as the launch of CI&T Business Builders and a partnership with Mistral in AI, indicate a focus on innovation and market expansion. Despite a slight decline in net profit margins from last year, CI&T's earnings are projected to grow annually by 19.17%. With its price-to-earnings ratio below the US market average and no significant shareholder dilution recently, CI&T presents an intriguing prospect within the penny stock landscape.

• Click here and access our complete financial health analysis report to understand the dynamics of CI&T.
• Learn about CI&T's future growth trajectory here.

Summing It All Up

• Click here to access our complete index of 316 US Penny Stocks.
• Searching for a Fresh Perspective? AI is about to change healthcare. These 129 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com